Clinical Read2026-06-01

Alrizomadlin (APG-115) with lisaftoclax (APG-2575)

Name: Alrizomadlin (APG-115) with lisaftoclax (APG-2575)
Start: 2026-06-01

Ascentage Pharma Group InternationalAAPG

Indication: Relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)
Stage: phase1
Event: Phase 1